Radiopharmaceuticals Market Research Reports & Industry Analysis
A radiopharmaceutical, which involves the use of radioactive agents in vivo to diagnose or treat specific diseases and conditions, generally consists of two components which determine its characteristics and clinical potential. The most common diagnostic molecular imaging agents use radioactive isotopes as the signal source. A radioactive isotope -- a radioisotope or radionuclide -- is a natural or artificially created isotope with an unstable nucleus that decays -- emitting alpha or beta particles, positrons, or gamma rays. As it decays, it loses mass and energy, until a stable isotope develops. For most elements, both stable and radioactive isotopes are known.
Examples of radioisotopes commonly combined with pharmaceutically-active molecules to form radiopharmaceuticals include technetium-99m, gallium-67, Iodine-123, Iodine-13, Thallium-201, Fluorine-18, and Indium-111.
A number of SPECT radiopharmaceuticals incorporate antibody and peptide formulations that can be targeted to specific tissue receptors, allowing one to discriminate healthy from diseased tissue with a high confidence level. However, the more specific the targeting agent is, the more difficult it is to interpret its position anatomically, since there are fewer landmarks.
Radiopharmaceuticals Industry Research & Market Reports
-
Global Lutetium-177(Lu-177) Market Research Report 2024
... forecast period 2024-2030. North American market for Lutetium-177(Lu-177) is estimated to increase from $ 1.33 billion in 2023 to reach $ 4.25 billion by 2030, at a CAGR of 15.81% during the forecast period of ... Read More
-
Diagnostic Radiopharmaceuticals & Contrast Media Market: Global Market Size, Forecast, Insights, and Competitive Landscape
... report on global diagnostic radiopharmaceuticals & contrast media market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. The report presents a clear picture of the global ... Read More
-
Radiopharmaceuticals Market: Global Market Size, Forecast, Insights, Segmentation, and Competitive Landscape with Impact of COVID-19 & Russia-Ukraine War
... report on global radiopharmaceuticals market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. The report presents a clear picture of the global radiopharmaceuticals market by segmenting ... Read More
-
Radiopharmaceutical Theranostics Market Size & Share Analysis - Growth Trends and Forecasts (2024 - 2029)
... billion by 2029, growing at a CAGR of 10.79% during the forecast period (2024-2029). The COVID-19 pandemic initially had a substantial impact on the radiopharmaceutical theranostics market. The pandemic caused delays and disruptions in ongoing ... Read More
-
Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030
... academic & research institute markets. The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030 with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market ... Read More
-
Radiopharmaceuticals Market Report by Product Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine), Application (Oncology, Cardiology, Neurology, Endocrinology, and Others), End Use (Hospitals and Clinics, Research Institutes, Diagnostic Centers), and Region 2024-2032
... size reached US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032. The radiopharmaceuticals market is primarily ... Read More
-
Nuclear Medicine Market Research Report Information by Type (Diagnosis [SPECT Radiopharmaceuticals {Tc99m, I-123, and Others} and PET Radiopharmaceuticals {F18, C11 Choline, and Others}] and Therapeutic (Alpha Emitters [Actinium-225 (Ac-225), Radium-223 (Ra-223), and Others], Beta Emitters [Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Others], and Brachytherapy Isotopes [Iodine-125 (I-125) and Others]), by Application (Neurology, Cardiology, Oncology [Prostate Cancer, Breast Cancer, Lung and Bronchus Cancer, Thyroid Cancer, Colorectal Cancer, and Others], and Others), by End User (Hospitals & Diagnostic Centers, Research Institutes, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) – Industry Forecast till 2032
... [Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Others], and Brachytherapy Isotopes [Iodine-125 (I-125) and Others]), by Application (Neurology, Cardiology, Oncology [Prostate Cancer, Breast Cancer, Lung and Bronchus Cancer, Thyroid Cancer, Colorectal Cancer, and Others], and Others), by ... Read More
-
Global Nuclear Medicine & Radiopharmaceuticals Market Size, Manufacturers, Opportunities and Forecast to 2030
... body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. ... Read More
-
Global Nuclear Medicine & Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030
... of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence ... Read More
-
Radiopharmaceuticals Industry Research Report 2024
... molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging ... Read More
-
Nuclear Medicine & Radiopharmaceuticals Industry Research Report 2024
... physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of ... Read More
-
Global Nuclear Medicine & Radiopharmaceuticals Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
... the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering ... Read More
-
Global Radiopharmaceuticals Market Size, Manufacturers, Opportunities and Forecast to 2030
... radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as ... Read More
-
Global Radiopharmaceuticals Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
... a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine ... Read More
-
Global Nuclear Medicine & Radiopharmaceuticals Market Analysis and Forecast 2024-2030
... by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static ... Read More
-
Global Radiopharmaceuticals Market Analysis and Forecast 2024-2030
... an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in ... Read More
-
Global Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030
... It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the ... Read More
-
Diagnostic Radiopharmaceuticals and Contrast Media
... is expected to reach US$13.6 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2023-2030. Contrast Media, one of the segments analyzed in the report, is expected to record a 4.2% ... Read More
-
Radiopharmaceuticals in Nuclear Medicine Market, By Product Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), By Application (Oncolog, Cardiology, Neurology, Endocrinology, Others), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
... Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) Radiopharmaceuticals are radioactive drugs used in nuclear medicine for both diagnostics and therapeutics purposes. These play a crucial role in medical imaging techniques ... Read More
-
Global Radiopharmaceuticals Market Size study, by Type (Diagnostic, Therapeutic), by Application (Cancer, Cardiology, Others), by Radioisotope (Technetium 99m, Gallium 68, Iodine I, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, Others), by End User (Hospitals and Clinics, Medical Imaging Centers, Others) and Regional Forecasts 2022-2032
... 177, Copper 67, Terbium 161, Zirconium 89, Others), by End User (Hospitals and Clinics, Medical Imaging Centers, Others) and Regional Forecasts 2022-2032 Global Radiopharmaceuticals Market is valued approximately at USD 7.9 billion in 2023 and ... Read More
-
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets
... develop assess the market, business/growth strategies, and make informed business decisions regarding radiation therapy products and services and radiopharmaceuticals. BCC Research estimates market data for 2023 (the base year) and forecasts values for 2024 through ... Read More
-
Imaging Agents
... at a CAGR of 4.5% over the analysis period 2023-2030. Diagnostic Radiopharmaceuticals, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$7.2 Billion by the end of ... Read More
-
Radiopharmaceuticals
... of 11.0% over the analysis period 2023-2030. SPECT Radioisotopes, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$6.2 Billion by the end of the analysis period. ... Read More
-
Global Radiopharmaceuticals Dispensing Isolator Market Growth 2024-2030
... the Radiopharmaceuticals Dispensing Isolator is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Radiopharmaceuticals Dispensing ... Read More
-
2024 Global: Nuclear Medicine/Radiopharmaceuticals Market - Innovative Markets Forecast (2030) report
... 2019 through 2030. Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2019 to 2030 using regression ... Read More
Research Assistance
